Qurasense, Inc.

Qvin develops non-invasive diagnostic solutions leveraging menstrual blood biomarkers for women's health screening and disease monitoring. The company's flagship product, the Q-Pad, is an FDA-cleared diagnostic menstrual pad that passively collects menstrual blood via an embedded Dried Menstrual Sample strip, enabling at-home collection of clinically valuable biospecimens without needles or invasive procedures. The Q-Pad has demonstrated strong clinical correlation with venous blood samples for biomarkers including HbA1c (r=0.96), TSH, and AMH (r>0.9), supporting its use in detecting and monitoring multiple conditions including diabetes, cervical cancer (HPV detection), endometriosis, sexually transmitted infections, and uterine fibroids. Qvin's research indicates menstrual effluent contains endometrial cells, immune components, hormones, and protein biomarkers reflective of both gynecological and systemic health, positioning it as an alternative to invasive biopsies, needle-based blood collection, and speculum-driven examinations such as Pap smears. The company partners with diagnostic platforms, healthcare organizations, and research institutions to expand the clinical validation and deployment of menstrual blood-based diagnostics. Qvin targets the women's health market, particularly addressing diagnostic access gaps in underserved populations. The company maintains an active research collaboration program with scientists, foundations, and non-profits to support clinical validation studies and innovation in period-blood diagnostics.